Ibogaine is unscheduled under Costa Rican law, meaning it is not explicitly prohibited or controlled as a narcotic substance, which has made Costa Rica one of the most active destinations for ibogaine treatment tourism in the Americas. Last verified: April 2026.

Current Legal Status

Costa Rica's drug control framework is governed primarily by Ley General de Salud (Law No. 5395) and the Ley sobre Estupefacientes, Sustancias Psicotrópicas, Drogas de Uso no Autorizado y Actividades Conexas (Law No. 8204). Ibogaine — the psychoactive alkaloid derived from the Tabernanthe iboga plant — does not appear on Costa Rica's official schedules of controlled or prohibited substances under either of these statutes.

Because ibogaine is neither explicitly permitted as a pharmaceutical nor listed as a controlled substance, it exists in a legal gray area: its importation, possession, administration, and use are not criminalized, but it also lacks formal regulatory approval from the Caja Costarricense de Seguro Social (CCSS) or the Ministerio de Salud as a licensed medicine. Clinics and treatment centers operating in Costa Rica typically do so under general health and wellness regulations rather than any ibogaine-specific framework.

There are no known religious carve-outs specific to ibogaine in Costa Rica, nor are there formal exemptions for research institutions. The current unscheduled status reflects the absence of legislation addressing ibogaine directly, not an affirmative policy endorsement of its use.

Key point: Unscheduled does not mean fully legal in a regulated sense. It means ibogaine is not listed among Costa Rica's controlled substances, allowing clinics to operate without the criminal liability found in countries like the United States or the United Kingdom.

Treatment Centers

Costa Rica hosts a notable number of ibogaine treatment centers, many of which cater specifically to international patients — particularly those traveling from the United States, Canada, and Europe where ibogaine is more strictly controlled. These facilities range from medically supervised retreats staffed by physicians and nurses to less formal wellness centers with varying levels of clinical oversight.

Centers are generally concentrated in areas popular with wellness tourism, including the Central Valley (near San José), the Pacific coast, and the Caribbean lowlands. Because there is no national licensing body specifically for ibogaine providers, the quality and safety standards of these facilities vary considerably.

For a full, vetted directory of clinics currently operating in Costa Rica, visit our ibogaine clinic directory.

How People Access Ibogaine in Costa Rica

The following reflects how ibogaine is factually accessed in Costa Rica. This is not a recommendation to pursue any particular course of action.

  • Treatment tourism: The most common pathway. Individuals — frequently those seeking treatment for opioid use disorder, PTSD, or depression — travel to Costa Rica specifically to undergo ibogaine therapy at private retreat centers or clinics. No prescription from a Costa Rican physician is legally required to receive ibogaine at these facilities.
  • Private clinics: Some clinics operate with a supervising physician on staff who conducts pre-treatment medical screening, including cardiac evaluations (EKG), liver function tests, and psychological assessments. The depth of this screening varies between providers.
  • Importation: Because ibogaine is unscheduled, its importation into Costa Rica for personal or clinical use is not subject to the criminal penalties applied to controlled substances. However, customs enforcement and Ministerio de Salud oversight could theoretically apply to importation of any substance deemed to pose a public health risk.
  • Combination programs: Some facilities offer ibogaine as part of broader integration programs that may include 5-MeO-DMT, ketamine, or other substances — each with their own distinct legal status in Costa Rica.
Important: Traveling with ibogaine or ibogaine-containing substances from Costa Rica back to a country where it is a controlled substance (such as the United States, United Kingdom, or Germany) carries serious legal risk in those destination countries, regardless of Costa Rican law.

Recent Legal Developments

Within the past two years, no formal legislation has been introduced in Costa Rica's Asamblea Legislativa to schedule, regulate, or ban ibogaine. The country has not moved toward either formal legalization with regulatory oversight or prohibition.

Regionally, growing international discussion around ibogaine's therapeutic potential — including ongoing clinical research in the United States and Australia — has generated some academic and medical interest in Costa Rica, but this has not yet translated into regulatory action by the Ministerio de Salud or CCSS.

Costa Rica's broader approach to drug policy has remained relatively stable. The country continues to prioritize harm reduction for traditional substances (alcohol, tobacco, cannabis) while ibogaine remains outside active legislative discussion. Observers in the ibogaine treatment community note that the absence of regulation, while permissive, also leaves patients without formal legal protections or quality standards enforceable by the state.

There have been no high-profile legal cases involving ibogaine providers or patients in Costa Rica that have prompted legislative review as of April 2026.

Risks of Seeking Treatment in Costa Rica

While Costa Rica's unscheduled status creates an accessible environment for ibogaine treatment, prospective patients should be aware of significant risks:

  • No standardized clinical oversight: The Ministerio de Salud does not currently license or inspect ibogaine clinics as a distinct category. Facilities operate under general health and business regulations, which means medical standards are self-imposed and highly variable.
  • Cardiac risk: Ibogaine is known to prolong the QTc interval and has been associated with cardiac arrhythmias and fatalities, particularly when administered without thorough pre-screening and continuous cardiac monitoring. Not all centers in Costa Rica maintain the equipment or staffing necessary to manage cardiac emergencies.
  • Drug interactions: Ibogaine carries serious and potentially fatal interaction risks with opioids, stimulants, antidepressants (particularly SSRIs and MAOIs), and other substances. The quality and thoroughness of intake screening varies significantly between providers.
  • No legal recourse framework: Because ibogaine treatment is not formally regulated, patients who experience harm may face challenges pursuing legal remedies through Costa Rican courts. Medical malpractice standards applicable to ibogaine-specific care are legally ambiguous.
  • Quality and purity of substances: Without regulatory oversight, the purity and accurate dosing of ibogaine used at any given facility cannot be guaranteed through a government-controlled supply chain. Reputable centers conduct third-party laboratory testing, but this is not universal.
  • Aftercare limitations: Costa Rica does not have a public health infrastructure specifically designed to support ibogaine integration or follow-up care. Patients returning home to other countries may find continuity of care difficult.
  • Travel considerations: International patients should verify their travel insurance covers treatment at unlicensed wellness facilities, as most standard policies exclude experimental or non-approved treatments.

Frequently Asked Questions

Ibogaine is unscheduled under Costa Rican law, meaning it is not listed as a controlled or prohibited substance under Law No. 8204 or the Ley General de Salud. It is not formally approved as a medicine either. This creates a legal gray area in which ibogaine is not criminalized, allowing clinics and retreat centers to operate without the legal prohibitions that exist in many other countries.
Traveling to Costa Rica for ibogaine treatment is not prohibited under Costa Rican law. However, you should carefully consider the laws of your home country. In the United States, for example, ibogaine is a Schedule I controlled substance, and while there is no general law criminalizing Americans for receiving treatment abroad, legal complexities may arise. Consult a licensed attorney in your jurisdiction before making travel decisions.
Medical supervision varies significantly between facilities. Some clinics employ licensed Costa Rican physicians and nurses, conduct thorough pre-treatment medical screening including cardiac EKG and blood work, and maintain emergency response capabilities on-site. Others offer more informal retreat-style programs with minimal medical infrastructure. Because there is no national licensing standard for ibogaine providers, prospective patients must conduct their own due diligence. Our clinic directory provides information to help evaluate individual centers.
No. Even if ibogaine is unscheduled in Costa Rica, importing it into a country where it is a controlled substance — such as the United States (Schedule I), United Kingdom (Class A), or Germany (Anlage I) — is a serious criminal offense under those countries' laws. The legal status in Costa Rica provides no protection from the laws of your destination country. Attempting to transport ibogaine across international borders carries significant legal risk.
Yes. Many clinics operating in Costa Rica specifically market ibogaine as a treatment for opioid use disorder, alcohol dependence, and other substance use disorders, as well as for mental health conditions such as PTSD and depression. However, ibogaine is not recognized or approved by Costa Rica's public health system (CCSS) for these indications, and treatment is delivered privately. Research into ibogaine's efficacy and safety continues internationally, but it is not yet an approved pharmaceutical treatment in any major regulatory jurisdiction.
Key factors to evaluate include: the presence of a licensed medical doctor and nursing staff on-site during treatment; mandatory pre-treatment cardiac screening (12-lead EKG) and liver function testing; documented protocols for managing cardiac emergencies; third-party laboratory verification of ibogaine purity and dosage; transparent disclosure of contraindications and drug interaction risks; clear aftercare and integration support; and verifiable reviews or referrals. Because there is no government licensing standard, patient-led research is essential. See our clinic directory for additional guidance.

Informational only. Not legal advice. Laws change. Verify with a licensed attorney before making any decisions.